541 related articles for article (PubMed ID: 27342992)
1. Negative feedback regulation of the ERK1/2 MAPK pathway.
Lake D; Corrêa SA; Müller J
Cell Mol Life Sci; 2016 Dec; 73(23):4397-4413. PubMed ID: 27342992
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
3. A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts.
Blüthgen N; Legewie S; Kielbasa SM; Schramme A; Tchernitsa O; Keil J; Solf A; Vingron M; Schäfer R; Herzel H; Sers C
FEBS J; 2009 Feb; 276(4):1024-35. PubMed ID: 19154344
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
[TBL] [Abstract][Full Text] [Related]
5. ERK1/2 in immune signalling.
Lucas RM; Luo L; Stow JL
Biochem Soc Trans; 2022 Oct; 50(5):1341-1352. PubMed ID: 36281999
[TBL] [Abstract][Full Text] [Related]
6. The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs).
Kidger AM; Keyse SM
Semin Cell Dev Biol; 2016 Feb; 50():125-32. PubMed ID: 26791049
[TBL] [Abstract][Full Text] [Related]
7. Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics.
Urasaki Y; Fiscus RR; Le TT
Sci Rep; 2018 Jul; 8(1):9991. PubMed ID: 29968772
[TBL] [Abstract][Full Text] [Related]
8. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
[TBL] [Abstract][Full Text] [Related]
9. The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy.
Xu Z; Sun J; Tong Q; Lin Q; Qian L; Park Y; Zheng Y
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941647
[TBL] [Abstract][Full Text] [Related]
10. Cigarette smoke exposure reveals a novel role for the MEK/ERK1/2 MAPK pathway in regulation of CFTR.
Xu X; Balsiger R; Tyrrell J; Boyaka PN; Tarran R; Cormet-Boyaka E
Biochim Biophys Acta; 2015 Jun; 1850(6):1224-32. PubMed ID: 25697727
[TBL] [Abstract][Full Text] [Related]
11. Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.
Marampon F; Ciccarelli C; Zani BM
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126017
[TBL] [Abstract][Full Text] [Related]
12. PKC isoenzymes differentially modulate the effect of thrombin on MAPK-dependent RPE proliferation.
Palma-Nicolas JP; López E; López-Colomé AM
Biosci Rep; 2008 Dec; 28(6):307-17. PubMed ID: 18636965
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
14. Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway.
Szybowska P; Kostas M; Wesche J; Wiedlocha A; Haugsten EM
Cells; 2019 May; 8(6):. PubMed ID: 31146385
[TBL] [Abstract][Full Text] [Related]
15. Marathon running increases ERK1/2 and p38 MAP kinase signalling to downstream targets in human skeletal muscle.
Yu M; Blomstrand E; Chibalin AV; Krook A; Zierath JR
J Physiol; 2001 Oct; 536(Pt 1):273-82. PubMed ID: 11579175
[TBL] [Abstract][Full Text] [Related]
16. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
[TBL] [Abstract][Full Text] [Related]
17. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells.
Liu S; Gao F; Wen L; Ouyang M; Wang Y; Wang Q; Luo L; Jian Z
Cell Physiol Biochem; 2017; 43(3):1100-1112. PubMed ID: 28977794
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents.
Singh VJ; Sharma B; Chawla PA
Bioorg Chem; 2021 Sep; 114():105161. PubMed ID: 34328852
[TBL] [Abstract][Full Text] [Related]
19. [Cell surface protein Ecm33 is involved in negative feedback regulation of MAP kinase signalling and development of the in vivo real-time monitoring of MAP kinase signalling].
Takada H
Yakugaku Zasshi; 2011; 131(8):1195-200. PubMed ID: 21804323
[TBL] [Abstract][Full Text] [Related]
20. Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models.
Vera J; Rath O; Balsa-Canto E; Banga JR; Kolch W; Wolkenhauer O
Mol Biosyst; 2010 Nov; 6(11):2174-91. PubMed ID: 20717620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
